ArticleAntimicrobial agents and chemotherapy2008
Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
Article in Antimicrobial agents and chemotherapy, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 2 syntheses or guidelines pooled it, 161 citations in OpenAlex.
- Ertapenem as an Antibiotic Prophylaxis for Colectomies and Laparotomies: A Systematic Review.Surgical infections · 2026Pooled it
- Infective Endocarditis byPathogens (Basel, Switzerland) · 2025Pooled it
- Efficacy and safety of moxifloxacin in hospitalized patients with secondary peritonitis: pooled analysis of four randomized phase III trials.Surgical infections · 2014Trial
- Repurposing Drugs as Bacteroides fragilis BFT-3 Inhibitors in the Animal Infection Model Galleria mellonella.Annals of the New York Academy of Sciences · 2026Article
- Clinical Significance ofMicroorganisms · 2026Article
- Case report: Analysis of the efficacy and safety of anti-infectious treatment for brain abscess caused by oral anaerobes.Frontiers in pharmacology · 2025Article
- Antimicrobial resistance pattern of anaerobic bacteria causing lower respiratory tract infections.BMC microbiology · 2023Article
- Anaerobic Gram-Negative Bacteria: Role as a Reservoir of Antibiotic Resistance.Antibiotics (Basel, Switzerland) · 2023Article
- Antimicrobial Susceptibility Profile of Rare Anaerobic Bacteria.Antibiotics (Basel, Switzerland) · 2022Article
- In Vitro Efficacy of Antibiotic Combinations with Carbapenems and Other Agents against Anaerobic Bacteria.Antibiotics (Basel, Switzerland) · 2022Article
- Article
- Distribution of anaerobic bacteria and their sensitivity pattern to several antibiotics at the clinical microbiology laboratory of school of medicine, universitas Indonesia, Jakarta in 2019-2020.Iranian journal of microbiology · 2022Article
- Microbiome of Odontogenic Abscesses.Microorganisms · 2021Article
- Phenotypic and genotypic antimicrobial resistance in clinical anaerobic isolates from India.JAC-antimicrobial resistance · 2021Article
- Clinico-microbiological profile ofThe Indian journal of medical research · 2021Observational
- Antibiotic resistance pattern of Bacteroides fragilis isolated from clinical and colorectal specimens.Annals of clinical microbiology and antimicrobials · 2021Article
- Comparison of Phenotypic and Genotypic Patterns of Antimicrobial-ResistantInfection and drug resistance · 2021Article
- Antimicrobial Resistance inMicrobiology spectrum · 2020Review
- Antimicrobial susceptibility against metronidazole and carbapenem in clinical anaerobic isolates from Pakistan.Antimicrobial resistance and infection control · 2019Article
- A Novel Selective Medium for Isolation of Bacteroides fragilis from Clinical Specimens.Journal of clinical microbiology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study reports data on the susceptibilities to five commonly used antianaerobic agents of five clinically frequently encountered anaerobes from 2000 to 2007 and to Bacteroides fragilis isolates causing nosocomial infections from 1990 to 2006. There was a trend of decreasing susceptibilities of these anaerobes to ampicillin-sulbactam, cefmetazole, chloramphenicol, and clindamycin with time during the study period. The rates of susceptibility to clindamycin and cefmetazole for all clinical isolates of Bacteroides fragilis isolates were higher than those of isolates associated with nosocomial infections. The MICs of 207 anaerobic blood isolates collected in 2006 to 14 antimicrobial agents were determined by the agar dilution method. The rates of nonsusceptibility to imipenem and meropenem were 7% and 12% for B. fragilis isolates (n = 60), 7% and 3% for Bacteroides thetaiotamicron isolates (n = 30), 4% and 4% for Fusobacterium species (n = 27), 6% and 0% for Prevotella species (n = 16), 15% and 0% for Clostridium species (n = 28), and 0% and 0% for Peptostreptococcus species (n = 32). The rates of susceptibility to moxifloxacin were 90% for B. fragilis isolates, 87% for B. thetaiotaomicron isolates, 81% for Fusobacterium species, 75% for Prevotella species, 93% for Clostridium species, and 78% for Peptostreptococcus species. Thirty-six percent of Clostridium species and 12% of Peptostreptococcus species were not susceptible to metronidazole. Comparison of the data with the data from a previous survey from the same institute in 2002 revealed higher rates of nonsusceptibility to carbapenems, especially for B. fragilis, Fusobacterium species, and Prevotella species isolates. The high rates of nonsusceptibility to commonly used antianaerobic agents mandate our attention, and periodic monitoring of the trend of the resistance is crucial.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.